Clinical Trials on Post Dialysis Arterio-Venous Fistula Puncture Sites in United Kingdom

Total 47 results

Methodist Health System

Enrolling by invitation

Outpatient Office Based Endovascular Procedures

Peripheral Arterial Disease | Varicose Veins | Chronic Venous Insufficiency | Dialysis Access Malfunction | Thoracic Outlet Syndrome | Arterio-venous Fistula | Vertebral Artery Insufficiency

United States
University of South Florida

Unknown

Hemodynamic Assessment of Distal Revascularization Interval Ligation (DRIL)

Chronic Kidney Diseases | Arterio-Venous Fistula | Steal Syndrome

United States
Alejandro Berenstein

Recruiting

PHIL® Embolic System Pediatric IDE

Intracranial Arteriovenous Malformations | Arterio-venous Fistula

United States
Laminate Medical Technologies

Completed

VasQ External Support for Arteriovenous Fistula

Diabetes Mellitus | Renal Failure | ESRD | Aneurysm | Kidney Failure | Renal Disease | Arterio-Venous Fistula | Steal Syndrome

United States
University of California, San Francisco

Completed

Endothelial Function and Arterio-Venous Fistula Maturation (EFAVF)

Chronic Kidney Disease

United States
Wake Forest University Health Sciences

Completed

Prefistula Forearm Exercise in Pts Requiring Chronic HD Therapy

Hemodialysis Access Failure | Kidney Failure | Arterio-venous Fistula

United States
Laminate Medical Technologies

Completed

VALUE- Vascular Access Laminate eUropean Experience. A Post Market Surveillance Study to Assess the Safety and Effectiveness of VasQ (VALUE)

Kidney Diseases | Kidney Failure, Chronic | ESRD | Renal Failure Chronic | Arterio-Venous Fistula | Arteriovenous Fistula Thrombosis

United Kingdom, Spain, Germany, France
University of Virginia
AstraZeneca

Completed

Determine the Safety/Efficacy of Ticagrelor for Maintaining Patency of Arterio-Venous Fistulae Created for Hemodialysis

End Stage Renal Disease | Vascular Access Patency

United States
Mayo Clinic

Recruiting

Florida Cerebrovascular Disease Biorepository and Genomics Center

Ischemic Stroke | Transient Ischemic Attack | Moyamoya Disease | Subarachnoid Hemorrhage | Vascular Dementia | Arteriovenous Fistula | Aneurysmal Subarachnoid Hemorrhage | Leukoaraiosis | Cerebrovascular Disease | Intracerebral Hemorrhage | Anoxic Brain Injury | Reversible Cerebral Vasoconstriction Syndrome | C... and other conditions

United States
Ayman Saad

Completed

Safety of Post-transplant Alpha-beta Depleted T-cell Infusion Following Haploidentical Stem Cell Transplant (Haplo SCT) (ABD)

Hematologic Neoplasms | Graft-Versus-Host Disease

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Institutes of Health (NIH)

Completed

Adoptive Immunotherapy With Activated Marrow Infiltrating Lymphocytes and Cyclophosphamide Graft-Versus-Host Disease Prophylaxis in Patients With Relapse of Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation

Hematologic Malignancies | Graft-Versus-Host Disease

United States
Medical College of Wisconsin

Active, not recruiting

Tildrakizumab for Prevention of Acute Graft-Versus-Host Disease

Hematologic Malignancies

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Leflunomide in Combination With Steroids for the Treatment of Acute Graft-versus-Host Disease After Donor Stem Cell Transplant for Hematologic Malignancies

Acute Graft Versus Host Disease | Hematopoietic and Lymphoid System Neoplasm

United States
Memorial Sloan Kettering Cancer Center
Millennium: The Takeda Oncology Company

Completed

Study of Ixazomib to Prevent Recurrent or Late Acute and Chronic Graft-versus-Host Disease 1-year After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Malignancies

Myeloid Hematologic Malignancy | Lymphoid Hematologic Malignancy

United States
University of Michigan Rogel Cancer Center

Completed

Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies

Hematologic Malignancies | Graft-Versus-Host Disease | Relapse

United States
National Cancer Institute (NCI)
National Institute of Neurological Disorders and Stroke (NINDS)

Recruiting

Optimizing PTCy Dose and Timing

Hematologic Neoplasms | Graft Versus Host Disease

United States
Ronald Paquette

Recruiting

Fludarabine and Total Body Irradiation 800 Centigray (cGy) or 1125 cGy For Allogeneic Stem Cell Transplant Using Graft Versus Host Disease Prophylaxis With Post-Transplant Cyclophosphamide and Tacrolimus, Without Mycophenolate Mofetil (OmitMMF)

Hematologic Neoplasms

United States
Dana-Farber Cancer Institute
Brigham and Women's Hospital; Millennium Pharmaceuticals, Inc.

Completed

Bortezomib Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease (GVHD) After Mismatched Allogeneic Non-Myeloablative Blood Stem Cell Transplantation

Hematologic Malignancies

United States
Dana-Farber Cancer Institute
Massachusetts General Hospital; Beth Israel Deaconess Medical Center; Brigham...

Completed

Tacrolimus, Sirolimus and Methotrexate as Graft Versus Host Disease Prophylaxis After Blood Stem Cell Transplantation

Hematologic Malignancies | Graft Versus Host Disease

United States
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Cell Selection for Bone Marrow Transplants to Prevent Graft-Versus-Host-Disease

Graft vs Host Disease | Hematologic Neoplasm

United States
Pavan Reddy, MD

Completed

Vorinostat to Prevent Graft Versus Host Disease Following Reduced Intensity, Related Donor Stem Cell Transplant

Graft vs Host Disease | Hematologic Malignancies

United States
Dana-Farber Cancer Institute

Terminated

Ex Vivo TCR αβ T Cell Depletion for Graft-Versus-Host Disease Prophylaxis in Mismatched Donor Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies

Hematologic Malignancy

United States
Nelson Chao
National Center for Advancing Translational Sciences (NCATS); Mereo BioPharma

Withdrawn

MPH966 for Prevention of Graft-versus-host Disease After Allogeneic Hematopoietic Stem Cell Transplantation

Hematologic Malignancy

United States
Spectrum Health Hospitals
Millennium Pharmaceuticals, Inc.

Completed

Post-Transplant Bortezomib and High Dose Cyclophosphamide as Graft-Versus-Host Disease (GVHD) Prophylaxis

Hematological Malignancy

United States
National Cancer Institute (NCI)

Completed

Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney Cancer

Renal Cell Carcinoma | Graft-Versus-Host Disease | Engraftment Syndrome

United States
Incyte Corporation

Terminated

GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease

Hematologic Malignancies

United States, Spain, France, Italy
University of British Columbia

Recruiting

Polyomic Biomarker Verification in Adult Chronic Graft-Versus-Host Disease (ABLE3.0/CTTC2201)

Leukemia | Allogeneic Hematopoietic Stem Cell Transplantation | Blood Cancer | Chronic Graft-versus-Host-Disease | Non-Malignant Hematologic and Lymphocytic Disorder

United States, Canada
University of British Columbia

Recruiting

Biomarker Verification in Pediatric Chronic GvHD: ABLE 2.0 / PTCTC GVH 1901 Study

Leukemia | Allogeneic Hematopoietic Stem Cell Transplantation | Blood Cancer | Chronic Graft-versus-Host-Disease | Non-Malignant Hematologic and Lymphocytic Disorder

United States, Canada
University of Chicago

Terminated

Minor Histocompatibility Vaccination After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malignancies

Lymphoma | Preleukemia | Myeloproliferative Disorders | Myeloma | Graft Versus Host Disease

United States
Ohio State University Comprehensive Cancer Center

Completed

Safety & Efficacy of Atorvastatin for Prophylaxis of Acute Graft Versus Host Disease in Patients With Hematological Malignancies HLA- Donor Hematopoietic Stem Cell Transplantation

Myelodysplastic Syndrome | Acute Lymphocytic Leukemia | Acute Myelogenous Leukemia

United States
Fate Therapeutics

Completed

Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Acute Lymphoblastic Leukemia | Chronic Myelogenous Leukemia | Hematologic Malignancies | Acute Graft-versus-host Disease

United States
Stanford University

Completed

Allogeneic Transplantation From Related Haploidentical Donors

Leukemia | MDS | NHL | Graft Versus Host Disease | Blood Cancer | Malignancy | CLL | Hodgkin's Disease

United States
Mesoblast International Sàrl
National Cancer Institute (NCI)

Withdrawn

OTI-010 for Graft-Versus-Host Disease Prophylaxis in Treating Patients Who Are Undergoing Donor Peripheral Stem Cell Transplantation for Hematologic Malignancies

Myelodysplastic Syndromes | Leukemia | Graft Versus Host Disease

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Completed

Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Other Hematologic or Metabolic Diseases

Myelodysplastic Syndromes | Leukemia | Thymic Carcinoma | Graft Versus Host Disease

United States
St. Jude Children's Research Hospital

Completed

Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow Transplantation for Hematologic Malignancies

Acute Lymphoblastic Leukemia | Chronic Myelocytic Leukemia | Myelodysplastic Syndrome | Acute Myelocytic Leukemia | Hodgkin's Disease

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell Transplant

Lymphoma | Myelodysplastic Syndromes | Leukemia | Testicular Germ Cell Tumor | Breast Cancer | Chronic Myeloproliferative Disorders | Ovarian Cancer | Gestational Trophoblastic Tumor | Neuroblastoma | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Diseases | Graft Versus Host...

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI); National Institutes of Health (NIH)

Terminated

T Cells in Predicting Acute Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant

Lymphoma | Myelodysplastic Syndromes | Leukemia | Testicular Germ Cell Tumor | Breast Cancer | Chronic Myeloproliferative Disorders | Ovarian Cancer | Gestational Trophoblastic Tumor | Neuroblastoma | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Neoplasms

United States
Northwestern University
National Cancer Institute (NCI)

Completed

Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Small Intestine Cancer | Multiple Myeloma and Plasma Cell Neoplasm | Graft Versus Host Disease | Precancerous/Nonmalignant Condition

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Small Intestine Cancer | Infection | Multiple Myeloma and Plasma Cell Neoplasm | Precancerous Condition | Graft Versus Host Disease | Myelodysplastic/Myeloproliferative Neoplasms | Secondary Myelofibrosis

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon

Lymphoma | Kidney Cancer | Myelodysplastic Syndromes | Leukemia | Testicular Germ Cell Tumor | Breast Cancer | Chronic Myeloproliferative Disorders | Ovarian Cancer | Gestational Trophoblastic Tumor | Neuroblastoma | Multiple Myeloma and Plasma Cell Neoplasm | Graft Versus Host Disease

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant

Follicular Lymphoma | Diffuse Large B-Cell Lymphoma | Hodgkin Lymphoma | Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Acute Leukemia | Myelodysplastic Syndrome | Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Myeloproliferative... and other conditions

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Campath-1H + FK506 and Methylprednisolone for GVHD

Lymphoma | Myelodysplastic Syndromes | Leukemia | Testicular Germ Cell Tumor | Breast Cancer | Chronic Myeloproliferative Disorders | Ovarian Cancer | Gestational Trophoblastic Tumor | Neuroblastoma | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Diseases | Graft Versus Host...

United States
Exai Bio Inc.

Recruiting

Prospective Study of oncRNA Stratification of Cancer by Size and Stage

Cancer

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies

Stage III Multiple Myeloma | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma and other conditions

United States
Sanford Health
National Ataxia Foundation; Beyond Batten Disease Foundation; Pitt Hopkins Research... and other collaborators

Recruiting

Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford (CoRDS)

Mitochondrial Diseases | Retinitis Pigmentosa | Myasthenia Gravis | Eosinophilic Gastroenteritis | Multiple System Atrophy | Leiomyosarcoma | Leukodystrophy | Anal Fistula | Spinocerebellar Ataxia Type 3 | Friedreich Ataxia | Kennedy Disease | Lyme Disease | Hemophagocytic Lymphohistiocytosis | Spinocerebellar Ataxia... and other conditions

United States, Australia
National Cancer Institute (NCI)

Completed

Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies

Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse... and other conditions

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant (GVHD)

Primary Myelofibrosis | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Juvenile Myelomonocytic Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal... and other conditions

United States

Clinical Trials on Post Dialysis Arterio-Venous Fistula Puncture Sites in United Kingdom

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saint Lucia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations